The use of unrelated bone marrow donors in the treatment of patients with chronic myelogenous leukemia: experience of four marrow transplant centers.
Thirty-seven patients with chronic myelogenous leukemia who lacked an HLA-identical sibling were transplanted with bone marrow from an HLA-A,B,DR-matched, one locus-mismatched, or two locus-mismatched unrelated volunteer donor. Twenty-two were in chronic phase and 15 had advanced to either accelerated phase or blast crisis. The projected 1000-day survival is 55% for chronic phase patients and 22% for accelerated or blast phase patients. For patients transplanted during chronic phase, results appeared to be comparable whether the donor was fully HLA-matched or HLA one locus-mismatched. These results indicate that marrow grafting from either HLA-identical or HLA one locus-mismatched volunteer donors may be effective therapy for patients with chronic myelogenous leukemia who lack an acceptable related donor.
Beatty
P G
PG
Fred Hutchinson Cancer Research Center, Seattle, WA 98104.
Ash
R
R
Hows
J M
JM
McGlave
P B
PB
D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation; D002986:Clinical Trials as Topic; D006680:HLA Antigens; D006650:Histocompatibility Testing; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology / Q000628:therapy*; D015465:Leukemia, Myeloid, Accelerated Phase / Q000276:immunology / Q000628:therapy; D015466:Leukemia, Myeloid, Chronic-Phase / Q000276:immunology / Q000628:therapy; D014184:Transplantation, Homologous
D006680:HLA Antigens